Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Bio-Techne (TECH)

NASDAQ: TECH · Life Sciences Tools & Services · Minneapolis, MN

Our rating: Neutral

Neutral reaffirmed at $72.83, moderate conviction, November 9, 2026.

Breaks if: The Neutral call turns Positive if Bio-Techne reports two consecutive quarters of organic revenue growth at or above 5% year over year, confirming the sector-cycle turn the multiple already implies. It turns Cautious if reported free cash flow falls below $55M in any single quarter (implying an annualized run rate below roughly $220M), signaling that the strong cash-conversion story is under real pressure — or if the stock falls more than 25% from today's $72.83 within twelve months without a corresponding recovery in reported growth.

Key figures

Market value$11.4B
Revenue, last 12 months$1.2B
Net income, last 12 months$172M
Free cash flow, last 12 months$308M
Price to earnings66.4×
Free cash flow yield2.7%
Dividend yield0.4%
Operating margin19.6%
Return on equity8.3%
Beta to the S&P 5000.98
Volatility, annualized41.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$300M4.6%$0.18$67M
June 30, 2026$321M1.3%$0.35$87M
March 31, 2026$311M−1.5%$0.32$78M
December 31, 2025$296M−0.4%$0.24$76M
September 30, 2025$287M−1.0%$0.24$22M
June 30, 2025$317M3.5%$-0.11$93M
March 31, 2025$316M4.2%$0.14$31M
December 31, 2024$297M9.0%$0.22$78M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

10 ledger entries and 47 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.